Role of glycol chitosan-incorporated ursolic acid nanoparticles in the treatment of osteosarcoma

Tropical Journal of Pharmaceutical Research

Volumn 14, Issue 9, 2015, Pages 1581-1588

  Zhang, Xing Lin ^a,b   Lu, Xing ^b   Geng, Wei ^c   Qu, Gao Wei ^b   Zhou, Zhi Yong ^b   Jiang, Lian Hong ^b   Li, Yun Xiang ^b   Chen, Xu ^b   Lin Nie, ^a  

^a SHANDONG UNIVERSITY   (China)

^b YANTAISHAN HOSPITAL   (China)

^c LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Cell cycle arrest; Glycol chitosan; Osteosarcoma; Palliation; Ursolic acid

Indexed keywords

CHITOSAN NANOPARTICLE; CYTOCHROME C; FLUORESCEIN ISOTHIOCYANATE; GLYCOL CHITOSAN NANOPARTICLE; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SINGLE STRANDED DNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; URSOLIC ACID;

APOPTOSIS; ARTICLE; BICINCHONINIC ACID ASSAY; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; FLOW CYTOMETRY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IC50; MTT ASSAY; OSTEOSARCOMA; PROTEIN EXPRESSION; SAOS 2 CELL LINE; U2OS CELL LINE; ULTRAVIOLET SPECTROPHOTOMETRY; WESTERN BLOTTING;

EID: 84943229942     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v14i9.6     Document Type: Article

References (23)

1. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009; 152: 239-262.
2. Janeway K, Gorlick R, Bernstein M. Osteosarcoma. In: Orkin S, Fisher D, Look A, Lux S, Ginsburg D, Nathan D, eds. Oncology of Infancy and Childhood. Philadelphia: Saunders Elsevier 2009: 871-910
3. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-441
4. Gorlick R, Toretsky J, Marina N. Bone tumors. In: Kufe D, Pollock R, Weichselbaum R, et al., eds. Cancer Medicine, 6th ed., Vol. 2. Hamilton, Ontario, Canada: BC Decker 2003; 2383-2406.
5. Marina N, Gorlick R, Bielack S. Pediatric osteosarcoma In: Carroll W, Finlay J, eds. Cancer in Children and Adolecents. Sudbury, MA: Jones and Bartlett 2010; 383-394.
6. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008; 10: 315-327.
7. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009; 9: 511-523.
8. Müller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2001; 2: 202-210.
9. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007; 8: 947-956.
10. Yeh ET. SUMOylation and De-SUMOylation: wrestling with life's processes. J Biol Chem 2009; 284: 8223-8227.
11. Kim JH, Baek SH. Emerging roles of desumoylating enzymes. Biochim Biophys Acta 2009; 1792: 155-162.
12. Bailey D, O'Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem 2004; 279, 692-703.
13. Cheng J, Wang D, Wang Z, Yeh ET. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol 2004; 24: 6021-6028.
14. Itahana Y, Yeh ET, Zhang Y. Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol 2006; 26: 4675-4689.
15. Zhang H, Saitoh H, Matunis MJ. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol Cell Biol 2002; 22: 6498-6508.
16. Zhu YM, Shen JK, Wang HK, Cosentino LM, Lee KH. Synthesis and anti-HIV activity of oleanolic acid derivatives, Bioorg. Med Chem Lett 2001; 11: 3115-3118.
17. Ma C, Nakamura N, Miyashiro H, Hattori M, Shimotohno K. Inhibitory effects of constituents from Cynomorium songaricum and related triterpene derivatives on HIV-1 protease, Chem Pharm Bull 1999; 47: 141-145.
18. Liu J. Pharmacology of oleanolic acid and ursolic acid, J Ethnopharmacol 1995; 49: 57-68.
19. Lee KH, Lin YM, Wu TS, Zhang DC, Yamagishi T, Hayashi T, Hall IH, Chang JJ, Wu RY, Yang TH. The cytotoxic principles of Prunella vulgaris, Psychotria serpens and Hyptis capitata: ursolic acid and related derivatives, Planta Med 1988; 54: 308-311.
20. Lin CN, Lu CM, Cheng MK, Gan KH, Won SJ. The cytotoxic principles of Solanum incanum, J Nat Prod 1990; 53: 513-516.
21. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beencher CW, Fong HH, Kinghorn AD, Brown DM, Wani MC, Wall ME, Hieken TJ, Gupta TKD, Pezzuto JM. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis, Nat Med 1995; 1: 1046-1051.
22. Sun IC, Chen CH, Kashiwada Y, Wu JH, Wang HK, Lee KH. Anti-AIDS agents: synthesis, anti-HIV and anti fusion activities of IC9564 analogues based on betulinic acid, J Med Chem 2002; 45: 4271-4275.
23. Harmand PO, Duval R, Delage C, Simon A. Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells, Int J Cancer 2005; 114; 1-11.